| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6703396 | JANSSEN PRODS | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| US7390791 | JANSSEN PRODS | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(11 months from now) | |
| US7700645 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Dec, 2026
(2 years from now) | |
| US8148374 | JANSSEN PRODS | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| US8754065 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| US9296769 | JANSSEN PRODS | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8597876 | JANSSEN PRODS | Method of treating HIV infection |
Jun, 2019
(4 years ago) | |
| US7470506 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US9889115 | JANSSEN PRODS | Fitness assay and associated methods |
Jun, 2019
(4 years ago) | |
| US6642245 | JANSSEN PRODS | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
| US7803788 | JANSSEN PRODS | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
| US10039718 | JANSSEN PRODS | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(8 years from now) | |
| US10786518 | JANSSEN PRODS | Compositions and methods of treating HIV |
Jul, 2038
(14 years from now) | |
Symtuza is owned by Janssen Prods.
Symtuza contains Cobicistat; Darunavir; Emtricitabine; Tenofovir Alafenamide Fumarate.
Symtuza has a total of 14 drug patents out of which 7 drug patents have expired.
Expired drug patents of Symtuza are:
- US8597876
- US7470506
- US9889115
- US6642245
- US7803788
- US6703396
- US8518987
Symtuza was authorised for market use on 17 July, 2018.
Symtuza is available in tablet;oral dosage forms.
Symtuza can be used as treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months, treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months, treatment of hiv-1 infection in adult or pediatric patients (>=40 kg) with <50 copies/ml hiv-1 rna after >= 6 months on prior antiretroviral regimen and no known darunavir or tenofovir resistance-associated substitutions, treatment of hiv-1 infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase in adults who are virologically suppressed on a stable antiretroviral regimen for at least 6 months.
Drug patent challenges can be filed against Symtuza from 06 November, 2019.
The generics of Symtuza are possible to be released after 19 July, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 i...
Dosage: TABLET;ORAL
SYMTUZA family patents
